



Relevance of admission hyperglycaemia and diabetes mellitus to efficacy and safety of mechanical thrombectomy in stroke patients

Anetta Lasek-Bal^{1,2}, Amadeusz Żak^{1,2}, Łukasz Binek², Sebastian Student^{3,4},
Aleksandra Cieślik¹, Wiesław Bal⁵, Wiktor Rybicki², Jolanta Kulawik-Szwajca⁶

¹Department of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, Poland

²Department of Neurology, Upper Silesian Medical Centre of the Silesian Medical University in Katowice, Poland

³Faculty of Automatic Control, Electronics and Computer Science, Silesian University of Technology, Gliwice, Poland

⁴Biotechnology Centre, Silesian University of Technology, Gliwice, Poland

⁵Department of Outpatient Chemotherapy, Maria Skłodowska-Curie Memorial Cancer Centre and Institute of Oncology, Gliwice, Poland

⁶Department of Rehabilitation, Murcki Hospital in Katowice, Poland

ABSTRACT

Introduction. The relevance of diabetes mellitus (DM) to the efficacy of mechanical thrombectomy (MT) has been the subject of few studies and with only inconclusive results.

Objectives. This study aimed to evaluate the effect of DM and admission hyperglycaemia on the efficacy and safety of MT in stroke patients.

Material and methods. This retrospective study analysis focused on the relevance of admission hyperglycaemia and DM to the functional status of patients treated with MT at the Upper Silesian Medical Centre of the Silesian Medical University in Katowice, Poland.

Results. 417 stroke patients (median age 70 years) were qualified for the study. There were 103 patients (24.70%) with DM. Admission hyperglycaemia ≥ 140 mg% was found in 91 patients (21.82%), of whom 69 were diagnosed with DM before or during hospitalisation. The parameters with the strongest effect on the functional status on days 7, 90 and 365 were: age, and neurological status according to the National Institutes of Health Stroke Scale (NIHSS) on the first day of ischaemic stroke before MT. The angiographic effect indirect after MT and patient functional status on days 7, 90 and 365 were comparable between the groups, regardless of the DM burden. The frequency of symptomatic intracranial bleeding 24 hours after MT was comparable between patients with and patients without DM ($p = 0.092$).

Model based on parameters were age, NIHSS on the first day of ischaemic stroke, an when score in Thrombolysis In Cerebral Infarct (TICI) showed good predictive attributes for the functional status of patients in the acute period (day 7). Age, a lack of admission hyperglycaemia, and the neurological state on day 1 of ischaemic stroke (before MT) were the key parameters for a favourable outcome (≤ 2 points on the modified Rankin Scale, mRS) on day 90. Admission hyperglycaemia ≥ 140 mg/dL, regardless of the presence or absence of DM, had a negative effect on achieving a good functional status one week after stroke onset.

Conclusions. Diabetes mellitus has a neutral effect on the angiographic and clinical outcomes of mechanical thrombectomy in stroke patients. It does not increase the risk of intracranial haemorrhage after instrumental therapy. It is admission hyperglycaemia, rather than diabetes mellitus, that is a predictor of poor functional status in patients treated with thrombectomy. According to our results, the patient's neurological status, age, and the outcome of thrombectomy are relevant to the functional status in the acute ischaemic stroke period.

Key words: stroke, thrombectomy, diabetes mellitus, mRankin, NIHSS

(*Neurol Neurochir Pol* 2022; 56 (6): 472–479)

Address for correspondence: Anetta Lasek-Bal, MD, PhD, Department of Neurology, School of Health Sciences, Medical University of Silesia in Katowice, Ziolowa Str. 45/47, 40–735 Katowice, Poland; e-mail: abal@sum.edu.pl

Received: 27.03.2022 Accepted: 12.09.2022 Early publication date: 17.11.2022

This article is available in open access under Creative Common Attribution-Non-Commercial-No Derivatives 4.0 International (CC BY-NC-ND 4.0) license, allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.

Introduction

Over the last five years, the evidence for the efficacy and safety of endovascular therapy in patients with stroke related to large vessel occlusion (LVO) has been growing. Recanalisation resulting from mechanical thrombectomy has been observed in up to 92% of patients, although only 46% of those were fully independent three months later [1, 2]. The main cause of failure is arterial reocclusion despite a previous successful angiographic result directly following an instrumental restoration of arterial patency. This applies to 9% of patients in the first 24 hours after MT [3–6]. DM increases the risk of stroke and of neurological deterioration in the acute phase of stroke, and the risk of stroke recurrence is also present [7–9]. It increases the risk of bleeding complications post-thrombolysis [10]. DM causes endothelial damage and impairment of cerebrovascular reactivity [11–14]. Metabolic disorders associated with DM, regardless of diabetic angiopathy, can adversely affect the nervous tissue during acute ischaemia. Previous studies have identified DM and hyperglycaemia on admission as important predictors affecting the outcomes in stroke patients treated with recanalisation therapies [15–17]. Hyperglycaemia in acute ischaemic stroke increases the risks of haemorrhagic transformation of an infarct focus, of haemorrhage following thrombolysis, and of death in the short-term follow-up after stroke [7, 10, 16, 18]. A probable mechanism for the adverse effects of hyperglycaemia is associated with increased blood-brain barrier permeability, impaired cerebrovascular reactivity, and increased susceptibility to reperfusion injury [18]. Negative effects concerning hyperglycaemia on metabolic processes in the penumbra can also be significant. Therefore, we should suspect that hyperglycaemia could impact upon the effect of mechanical thrombectomy and be relevant to the functional status of the patient, especially in the acute period. Patients with admission hyperglycaemia and hyperglycaemia on the first day of stroke significantly less frequently return to a favourable functional status following MT than do those with normal admission glycaemia [19].

In recent years, the effects of stress hyperglycaemia (SH) due to stroke in patients burdened with DM, and in those with no such burden, have been receiving some attention [20–22]. The phenomenon of SH has not been investigated in depth. The mechanisms of the effect of SH and DM-related hyperglycaemia on neural tissue are different, and the clinical sequelae in stroke patients may vary. Determining the impact of hyperglycaemia and DM on MT outcomes might modify the selection criteria for endovascular stroke therapy. It could also allow us to optimise the management of hyperglycaemic therapy in the acute stroke period.

The purpose of this study was to evaluate the effect of DM and hyperglycaemia upon hospital admission, and on the efficacy and safety of MT in patients with acute ischaemic stroke associated with LVO.

Material and methods

This retrospective study included patients hospitalised in the Upper Silesian Medical Centre of the Silesian Medical University in Katowice between 2019 and 2021 because of stroke. The patients met the main criterion — they suffered from stroke in the course of large vessel occlusion and they were treated with MT within six hours following stroke onset. We did not qualify cases with incomplete medical data. In this study, all patients were analysed based on age at the time of their first stroke, the presence of comorbidities (DM, atrial fibrillation (AF), arterial hypertension (AH), coronary heart disease (CHD), lipid disorders (LD), > 70% atherosclerotic carotid artery stenosis (CAS, ipsilaterally to the acute ischaemic brain lesion), peripheral artery disease (PAD) in lower extremities, blood glucose concentration when admitted to hospital, the angiographic effect according to the score in TICI directly after MT, and the rate of intracranial bleeding (ICB) after MT including symptomatic ICB (sICB). Neurological status on the first day of stroke was evaluated using the NIHSS and the functional status according to the mRS was examined on days 7, 90 and 365 after stroke, in accordance with the mRS scale.

AF was diagnosed on the basis of previous patient records or electrocardiogram (ECG), or 24-hour ECG monitoring performed during stroke-related hospitalisation.

AH was diagnosed in accordance with the recommendations of the European Society of Cardiology [23]. The diagnosis of DM was based on previous medical history or it was made by a diabetologist during hospitalisation. Diagnostic criteria for DM included the following: a fasting plasma glucose level ≥ 126 mg/dL (7.0 mmol/L), or 2-hour plasma glucose level ≥ 200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test, or a random plasma glucose level ≥ 200 mg/dL (11.1 mmol/L) in a patient with classic symptoms of hyperglycaemia, or a haemoglobin A1c (HbA1c) level $\geq 6.5\%$. Blood glucose level ≥ 140 mg/dL on admission to hospital was defined as admission hyperglycaemia. A diabetologist consulted each patient with incorrect admission glycaemia (≥ 140 mg/dL).

LD were defined according to the ESC Guidelines for the Management of Dyslipidemias. LD were diagnosed when at least one of the following features was present: hypercholesterolemia with total cholesterol concentration ≥ 5 mmol/ml (≥ 190 mg/dL) or LDL-C ≥ 3 mmol/l (≥ 115 mg/dL) and/ or hypertriglyceridemia with triglyceride concentration ≥ 1.7 mmol/l (≥ 150 mg/dL).

The NASCET (North American Symptomatic Carotid Endarterectomy Trial) criteria were used to assess the degree of stenosis of the common carotid artery and/or internal carotid artery.

Haemorrhagic lesions were evaluated based on a head CT performed 24 hours after MT and using the European Cooperative Acute Stroke Study (ECASS) scale. ICB was defined as symptomatic when the neurological status deteriorated due to ICB, with an increase of at least 4 points on the NIHSS during

the 24 hours following MT (i.e. the difference between the NIHSS evaluated before MT and 24 hours after the procedure).

Explanation of mechanical thrombectomy method

The hospital's Interventional Neuroradiology Department performed the mechanical thrombectomy procedures using a Siemens Axiom Artis Zee Bi-Plane machine, a state-of-the-art device. Alternatively, if the angi suite was unavailable, a monoplane machine was available for the procedure to be performed in the Vascular Surgery Cath-lab or the Interventional Cardiology Cath-lab. The patient underwent general anaesthesia or conscious sedation in accordance with their preference and/or clinical condition. MT was performed by a single operator who was part of a multidisciplinary team composed of two neuroradiologists, three vascular surgeons, and four interventional cardiologists. Neurologists initially qualified the patients, arranged the logistics, and provided postoperative care.

MT was commonly performed with stent retrievers (Trevor, Catch, Soliter, Tiger) and an 8F Balloon Guide Catheter (Flow Gate 2). In a few cases, distal aspiration (Penumbra, Sofia, Cathalyst) or a combination of stent retrievers and distal aspiration was used.

After consulting a legal opinion, the approval of the Bioethics Committee of the Medical University of Silesia in Katowice was not required, since this study was not a medical experiment.

Statistical analysis

The prevalence of comorbidities or specific conditions listed above was assessed among all the patients, and after dividing them into those with DM and those without it. The results obtained in the mentioned groups were compared.

Multivariate analysis was then performed to identify the factors which were important for obtaining a good angiographic effect (TICI = 2b-3) after MT, as well as those concerning the functional status of all the patients and of those with DM on days 7, 90 and 365.

We constructed multivariable models using ordinal logistic regression for ordinal outcomes. Model variable selection procedures covered automatic selection (stepwise, forward and backward) as determined in accordance with the AIC and BIC criteria. The accuracy of model predictions was evaluated by implementing the multiclass AUC estimator and the leave-one-out procedure. R 3.6.1 was used to perform all statistical analyses.

Logistic regression was used to analyze the following variables: age, sex, AF, AH, CHD, DM, LD, > 50% CAS, smoking, TICI, PAD, sICD after intervention, NIHSS before MT, recombinant tissue plasminogen activator (rtPA), pre-stroke anticoagulation, pre-stroke antiplatelet therapy, hemicraniectomy, and glycaemia ≥ 140 mg% upon admission. These same parameters were analysed as being independent factors for

a good functional state (mRS ≤ 2) of stroke patients on three time points after MT (i.e. on days: 7, 90, and 365 after stroke onset). An analysis of the potential impact of admission hyperglycaemia as well as of DM on the functional status at two time points (days 7 and 90) was also performed.

The size of each subgroup was determined using Chi squared power calculation, i.e. by assuming a significance level of 0.05, we calculated that to achieve the test power of 0.8, each of the groups would have 54 patients. The condition was met, but not for the group with hyperglycaemia, and we recommend careful interpretation of the results.

Results

Our study eventually enrolled 417 patients treated with mechanical thrombectomy for cerebral stroke. A total of 421 stroke patients, median age 70 years (range 20–92), 47.7% of them female, who were admitted and hospitalised in 2019–2021 and who were treated in the ultra-acute ischaemic stroke period (≤ 6 hours) with mechanical thrombectomy, were initially qualified for the retrospective study. We excluded (because of incomplete medical records) four patients who underwent MT. Of the 417 patients included, 254 (61.2%) were treated with rtPA + MT.

The study group included 134 (32.13%) patients undergoing antithrombotic therapy. Because of AF, 55 (13.18%) patients used anticoagulation therapy (for at least one month before MT) — 24 patients were using warfarin, 16 were using rivaroxaban, eight were using dabigatran, and seven were using apixaban. The correct therapeutic results of INR (2.5–3.2) were observed in 16 patients (66.6% of whom used warfarin). The other 79 (18.94%) patients used antiplatelet therapy including aspirin — 51 (12.23%) in monotherapy, 16 (3.83%) clopidogrel, and 12 (2.87%) a duotherapy of aspirin with clopidogrel.

103 patients with DM were included in the study group (24.70%). DM patients were not significantly different from DM-free patients in terms of their mean age. The mean duration of DM (from the time of diagnosis) in the study group was 12 years [0–21 years]. 23 patients with DM (21.35%) had used insulin therapy before stroke onset. Mean blood glucose upon hospital admission was 87 mg/dL [79–419 mg/dL], and in diabetic patients it was 129 mg/dL [81–419 mg/dL]. Hyperglycaemia ≥ 140 mg/dL was found in 91 patients (21.82%), of whom 69 were diagnosed with DM before or during hospitalisation, including two diagnosed with DM associated with chronic steroid therapy. In seven individuals (1.67%), hyperglycaemia was present upon admission but disappeared completely in the three days following stroke onset. In these cases, we identified probable stroke-associated hyperglycaemia.

The patients with DM were burdened with AF, PAD, AH and LD significantly more often than those without DM (Tab. 1).

Table 1. Characteristics of patients with and without diabetes mellitus

| Parameters | All patients n = 417 | DM patients n = 103 | Patients without DM n = 314 | FDR-adjusted p-value (DM patients vs. patients without DM) |
|--------------------------------------|-------------------------|----------------------------|--------------------------------|--|
| Age [mean ± SD] | 67.8 ± 13.2 | 70.70 ± 10.46 | 66.82 ± 13.92 | 0.138 |
| mean [med. range] | 70 [20–92] | 70 [42–92] | 69 [20–89] | |
| F/M | 199/218 | 53/50 | 146/168 | 0.670 |
| AF | 108 (26.0%) | 36 (34.95%) | 72 (22.92%) | 0.015 |
| AH | 315 (75.5%) | 90 (87.37%) | 218 (69.42%) | < 0.001 |
| LD | 168 (40.4%) | 48 (46.6%) | 104 (33.12%) | 0.013 |
| PAD in lower limbs | 216 (51.79%) | 67 (65.04%) | 149 (47.45%) | < 0.001 |
| CAS | 51 (12.1%) | 13 (12.62%) | 29 (9.23%) | 0.32 |
| Previous TIA/stroke burden | 89 (21.3%) | 21 (20.38%) | 68 (21.65%) | 0.42 |
| Smoking | 126 (30.2%) | 39 (37.86%) | 87 (27.70%) | 0.29 |
| NIHSS mean [med. range] | 12.8 ± 5.6 12 [0–43] | 13.50 ± 5.68 [13; 3–30] | 12.61 ± 5.52 [12; 0–43] | 0.385 |
| rtPA | 254 (61.2%) | 59 (57.28%) | 196 (62.42%) | 0.670 |
| Hemicraniectomy | 23 (5.5%) | 3 (2.91%) | 20 (6.36%) | 0.548 |
| Antithrombotic therapy before stroke | 134 (32.1%) | 44 (42.71%) | 90 (28.66%) | 0.099 |
| Stroke in summer season | 225 (53.95%) | 56 (54.36%) | 169 (53.82%) | 1 |
| TICI 2b-3 | 274 | 67 (65.04%) | 207 (65.92%) | 1 |
| sICB | 95 | 31 (30.09%) | 64 (20.38%) | 0.092 |
| mRS_7d | 3.93 ± 1.69 | 4.05 ± 1.69 | 3.82 ± 1.77 | 0.548 |
| mRS_90d | 3.77 ± 1.86 | 3.94 ± 1.87 | 3.62 ± 1.93 | 0.372 |
| mRS_12m | 3.82 ± 1.71 | 4 ± 1.82 | 3.65 ± 1.91 | 0.349 |

AF — atrial fibrillation; AH — arterial hypertension; CAS — carotid artery stenosis; EF — ejection fraction; F — female; FDR — false discovery rate; LD — lipid disorders; M — male; NIHSS — National Institutes of Health Stroke Scale at baseline; PAD — peripheral artery disease; rtPA — recombinant tissue plasminogen activator; sICB — symptomatic intracranial bleeding; mRS — modified Rankin Scale; mRS_7 — modified Rankin Scale on 7th day after stroke; mRS_90 — modified Rankin Scale on 90th day after stroke; mRS_12m — modified Rankin Scale 12 months after stroke; TICI — thrombolysis in cerebral infarction

Patient functional status on days 7, 90 and 365 was comparable between groups regardless of the DM burden. The burden of the sICB was comparable between patients with and without DM (Tab. 1).

Age, lack of admission hyperglycaemia, and neurological state according to NIHSS on the 1st day of stroke (before MT) were the key parameters for a favourable outcome on day 90 (Tab. 2).

We did not identify the important parameters for obtaining the TICI 2b-3 by analysing the same parameters as listed in the tables above (Suppl. Tab. 1).

In multivariate analysis related to all of the patients, the parameters with the strongest effect on the functional status on days 7, 90 and 365 were: age and NIHSS on the first day of stroke before MT. The model based on attributes: age, NIHSS on the first day of stroke, TICI showed good predictive attributes for the functional status of patients in the acute period (day 7) (Tab. 3).

DM burden was not a statistically significant independent factor for the functional status at the three time-points under study: on days 7, 90 and 365 after the onset (Tab. 3, Suppl. Fig. 1). Hyperglycaemia ≥ 140 mg/dL upon hospital admission, regardless of the presence or absence of DM, had a negative

effect on achieving a good functional status one week after onset (Table 4). Admission hyperglycaemia had a neutral impact on the functional state on the day 90 (Tab. 4).

In univariate analysis related to diabetic patients with admission hyperglycaemia, the following key factors were identified for achieving a good functional state: NIHSS score before MT for a good functional state on day 7 (FDR-adjusted p-value = 0.018), and a lack of peripheral artery disease for a good functional state on day 90 (FDR-adjusted p-value = 0.033). In diabetic patients without admission hyperglycaemia, we did not identify any independent parameter with a strong effect on functional status on day 7, and we identified only one factor for obtaining a good status on day 90 i.e. the NIHSS score before MT (FDR-adjusted p-value = 0.013).

Discussion

The main finding of our study is that admission hyperglycaemia in the ultra-acute period of stroke, and not the presence of DM, is an *a priori* parameter relevant to the clinical effect of MT as expressed by the functional status of patients in the acute period of stroke.

Table 2. Characteristics of patients with good and poor functional status according to mRS on 90th day after mechanical thrombectomy

| Parameters | All patients n = 417 | Patients with 0-2 mRS n = 120 | Patients with 3-6 mRS n = 297 | FDR-adjusted p-value |
|--|------------------------------|----------------------------------|----------------------------------|-------------------------|
| Age [mean ± SD] | 67.8 ± 13.2 | 64.83 ± 13.02 | 68.96 ± 13.17 | 0.009 |
| mean [med. range] | 70 [20–92] | 67 [23–89] | 72 [20–92] | |
| F/M | 199/218 | 552/68 | 147/150 | 0.631 |
| AF | 108 (26.0%) | 29 (24.16%) | 79 (26.59%) | 0.752 |
| AH | 308 (75.5%) | 85 (79.83%) | 223 (75.08%) | 0.752 |
| LD | 152 (40.43%) | 43 (35.83%) | 109 (36.7%) | 0.752 |
| PAD in lower limbs | 216 (52.94%) | 67 (55.83%) | 149 (50.16%) | 0.603 |
| CAS | 42 (12.1%) | 10 (8.33%) | 32 (10.77%) | 0.631 |
| Smoking | 115 (37.1%) | 29 (24.16%) | 86 (28.95%) | 0.631 |
| Hyperglycaemia | 31 (7.43%) | 1 (0.83%) | 30 (10.10%) | 0.012 |
| DM | 103 (25.31%) | 24 (20%) | 79 (26.59%) | 0.557 |
| NIHSS mean [med. range] | 12.8 ± 5.6 12 [0–43] | 9.96 ± 4.96 [0–26] | 13.99 ± 5.39 [3–43] | < 0.001 |
| rtPA | 255 (61.45%) | 76 (63.33%) | 179 (60.26%) | 0.752 |
| Hemicraniectomy | 23 (5.52%) | 2 (1.66%) | 21 (7.07%) | 0.238 |
| Antithrombotic therapy before stroke | 134 (32.13%) | 36 (30%) | 98 (32.99%) | 0.752 |
| Stroke in summer season | 225 (53.96%) | 69 (57.5%) | 156 (52.52%) | 0.646 |
| Stroke onset to groin puncture time mean [med. range] | 255.3 ± 67.44 255 [5–405] | 245.7 ± 73.30 [5–395] | 259.1 ± 64.78 [72–405] | 0.361 |

AF — atrial fibrillation; AH — arterial hypertension; CAS — carotid artery stenosis; EF — ejection fraction; F — female; FDR — false discovery rate; LD — lipid disorders, M — male; NIHSS — National Institutes of Health Stroke Scale at baseline; PAD — peripheral artery disease; rtPA — recombinant tissue plasminogen activator

Table 3. Ordinal regression analysis of influence of clinical phenodata on mRS (0–2 points) — 7th day, 90th day and 12th month after stroke onset

| Coefficients | OR | CI 95% | p-value |
|--|-------|---------------|----------|
| mRS- 7th day (mcAUC = 0.769, AIC = 128.06) | | | |
| Age | 1.034 | (1.009–1.06) | < 0.01 |
| NIHSS 1d | 1.103 | (1.039–1.174) | < 0.01 |
| TICI | 0.506 | (0.255–0.976) | 0.04 |
| mRS 90th day (mcAUC = 0.707, AIC = 98.48) | | | |
| Age | 1.082 | (1.032–1.143) | < 0.01 |
| NIHSS 1d | 1.269 | (1.124–1.461) | < 0.0001 |
| TICI | 0.294 | (0.08–1.002) | 0.05 |
| mRS 12th month (mcAUC = 0.704, AIC = 94.87) | | | |
| Age | 1.098 | (1.038–1.171) | 0.0002 |
| NIHSS | 1.269 | (1.107–1.495) | 0.002 |

DM — diabetes mellitus; LD — lipid disorders; mRS — modified Rankin Scale; NIHSS 1d — NIHSS on the 1st day of stroke; TICI — thrombolysis in cerebral infarction

In this respect, the results of our study have confirmed previous observations made by other authors. But what is new is the finding that the presence of DM is not a sufficient parameter to influence the effect of MT, except when the patient’s admission hyperglycaemia is above the threshold value adopted in this study. Only in combination with the neurological status, patient age, and angiographic outcome of

Table 4. Admission hyperglycaemia and functional state in diabetic and non-diabetic patients

| Parameter | Groups | Chisq | Chisq FDR corrected p-value |
|-----------------------------|------------------------------------|----------|--------------------------------|
| mRS 7th day | | | |
| Admission hyperglycaemia | mRS < 3 vs. mRS ≥ 3 | 0.013 | 0.009 |
| DM/admission hyperglycaemia | mRS < 3 vs. mRS ≥ 3 in DM+ vs. DM- | 9.28E-05 | 0.046 |
| mRS 90th day | | | |
| Admission hyperglycaemia | mRS < 3 vs. mRS ≥ 3 | 6.18E-06 | 0.133 |
| DM/admission hyperglycaemia | mRS < 3 vs. mRS ≥ 3 in DM+ vs. DM- | 5.36E-06 | 0.124 |

DM — diabetes mellitus; FDR — false discovery rate; mRS — modified Rankin Scale

thrombectomy was DM significant for the functional status in the acute ischaemic stroke period.

Until now, several independent factors for an unfavourable prognosis of patient functional status have been identified at three months following MT performed for cerebral stroke. These factors include an older patient’s age, a low Alberta Stroke Program Early CT Score (ASPECTS), and a high NIHSS

score [25, 26]. The data related to the significance of the other clinical parameters, as well as logistic parameters and technical aspects related with MT, are inconsistent or are still under evaluation [24, 26, 27]. In the last three years, there has been an increase in publications discussing the effect of DM on MT outcomes. DM and hyperglycaemia at hospital admission have been shown to have a negative effect; however, the results of previous studies are inconsistent [16, 17, 25, 28–31]. DM was identified via the GADIS score as being a significant factor for those associated with poor functional status of stroke patients treated with thrombectomy [32]. DM is not only a risk factor for atherosclerosis and stroke, but also for stroke recurrence and an early neurological deterioration in acute ischaemic stroke patients [7–9].

It is believed that due to coagulation-fibrinolysis imbalance and incorrect platelet activity, patients with DM are in a state of chronic hypercoagulability [33, 34]. Hyperglycaemia correlates with an increase in the volume of brain infarct in patients who have been subjected to thrombolytic therapy [10]. DM also increases the risk of haemorrhagic transformation of cerebral infarction in patients who have undergone thrombolysis and MT [35]. In diabetic patients, the hyperglycaemic environment contributes to poor development of collaterals (and volume of the infarct focus) [36]. Collateral failure is a result of diabetic microangiopathy. Borggrefe et al. have shown that the condition of collaterals is associated with hyperglycaemia in stroke patients [25]. The disease can impair revascularisation and reperfusion and it can increase reperfusion injury to neural tissue [36]. In our study, we did not determine an increase in the incidence of intracerebral haemorrhage in diabetic patients on the first day after MT.

According to data published previously, in stroke patients treated with MT the risk of intracranial haemorrhage is associated with some admission parameters, including hyperglycaemia, but not with a history of DM [37–39]. The cumulative outcome of the effect of the chronic influence of hyperglycaemia in DM and of the acute influence of MT on the endothelium may account for poorer outcomes in this patient group and for long-term follow-up results. The effect of hyperglycaemia on the structure of a thrombus occluding a large artery should also be taken into consideration. The structure of a thrombus obtained during MT from patients with DM and stroke has dominant fibrin, instead of the red blood cells which are typical for thrombus in non-diabetic patients [29]. Most probably, the composition of thrombus in DM patients makes it harder to mechanically remove it or aspirate it, which is important for the prognosis of post-stroke condition in such patients.

According to an analysis of the SWIFT trial results, hyperglycaemia increases the risk of a worse outcome at three months in post-stroke patients [40]. In the MR CLEAN study, admission hyperglycaemia (141 mg/dL) and fasting glucose (99 mg/dL) seriously increased the risk of symptomatic intracranial

haemorrhage and poor functional status [41]. According to these reports, an admission glucose level > 110 mg/dL is associated with a low rate of good clinical outcomes after MT, and glucose levels > 170 mg/dL are associated with a high risk of parenchymal haematoma [42].

Hyperglycaemia can be also caused by stress resulting from stroke. In this case, hyperglycaemia is not associated with the metabolic processes observed in DM, such as insulin resistance increasing plasminogen activator inhibitor secretion and modifying fibrinolytic activity. SH is mediated by the hypothalamic-pituitary-adrenal axis, the sympatho-adrenal system, and pro-inflammatory cytokines that cause a stress response with excessive gluconeogenesis, glycogenolysis, and insulin resistance [43].

While diabetes mellitus is a recognised risk factor for cerebrovascular diseases, the consequences of stress hyperglycaemia are not well-established. However, stress hyperglycaemia has been shown to have a negative impact on the post-stroke functional status of patients [20–22]. The mechanisms underlying the association between SH and poor clinical outcomes in stroke patients are not completely understood. Hyperglycaemia might directly cause toxic damage to the ischaemic brain due to the accumulation of lactate and intracellular acidosis; the stress-induced inflammatory response may increase circulating free fatty acids in patients with acute illnesses, thus impairing endothelium-dependent vasodilation, and SH may lead to reperfusion injury due to increased oxidative stress and inflammation [44–46]. Hyperglycaemia may augment endothelial damage at the site of contact between the endothelium and the tools used during thrombectomy.

The phenomenon of hyperglycaemia, although not fully understood as such, is both interesting and important from a practical perspective. This supports a strategy of glycaemic monitoring starting immediately after the stroke. The American Heart Association recommends close glucose monitoring on the first day of stroke in patients with values higher than 140 mg/dL [47]. Regardless of all the supporting data, the Cochrane review found that insulin therapy to keep glucose levels within normal range has no long-term benefit for the neurological status or mortality parameters, and that it increases the incidence of hypoglycaemic episodes [48].

This demonstrates that diabetic patients with acute ischaemic stroke face complex problems beyond, and independent of, the other well-known modifiable and unmodifiable parameters related to all stroke patients [49, 50].

Our study has some limitations, the most important being as follows: this was a single-center study and a retrospective study; we made no comparison between MT effects and thrombectomy types, and there was a lack of information concerning the use of statins before stroke. The majority of patients (274; 65.7%) were referred to us from other hospitals (the so-called drip-and-ship model) without complete data.

Conclusions

Diabetes mellitus has a neutral effect on the angiographic and clinical outcomes of mechanical thrombectomy in stroke patients. It does not increase the risk of intracranial haemorrhage after instrumental therapy. It is admission hyperglycaemia, and not diabetes mellitus, that is a predictor of poor functional status in patients treated with thrombectomy. According to our results, the patient's neurological status, age, and the outcome of thrombectomy, are the factors relevant to the functional status in the acute ischaemic stroke period.

Conflict of interest: *None.*

Funding: *None.*

References

- Goyal M, Menon BK, van Zwam WH, et al. HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet*. 2016; 387(10029): 1723–1731, doi: [10.1016/S0140-6736\(16\)00163-X](https://doi.org/10.1016/S0140-6736(16)00163-X), indexed in Pubmed: [26898852](https://pubmed.ncbi.nlm.nih.gov/26898852/).
- Yoo AJ, Soomro J, Andersson T, et al. Benchmarking the extent and speed of reperfusion: first pass tICI 2c-3 is a preferred endovascular reperfusion endpoint. *Front Neurol*. 2021; 12: 669934, doi: [10.3389/fneur.2021.669934](https://doi.org/10.3389/fneur.2021.669934), indexed in Pubmed: [34046008](https://pubmed.ncbi.nlm.nih.gov/34046008/).
- Zhao W, Shang S, Li C, et al. Long-term outcomes of acute ischemic stroke patients treated with endovascular thrombectomy: a real-world experience. *J Neurol Sci*. 2018; 390: 77–83, doi: [10.1016/j.jns.2018.03.004](https://doi.org/10.1016/j.jns.2018.03.004), indexed in Pubmed: [29801912](https://pubmed.ncbi.nlm.nih.gov/29801912/).
- Janjua N, Alkawi A, Suri MFK, et al. Impact of arterial reocclusion and distal fragmentation during thrombolysis among patients with acute ischemic stroke. *AJNR Am J Neuroradiol*. 2008; 29(2): 253–258, doi: [10.3174/ajnr.A0825](https://doi.org/10.3174/ajnr.A0825), indexed in Pubmed: [18024576](https://pubmed.ncbi.nlm.nih.gov/18024576/).
- Tsang AC, Orru E, Klostranec JM, et al. Thrombectomy outcomes of intracranial atherosclerosis-related occlusions. *Stroke*. 2019; 50(6): 1460–1466, doi: [10.1161/STROKEAHA.119.024889](https://doi.org/10.1161/STROKEAHA.119.024889), indexed in Pubmed: [31084327](https://pubmed.ncbi.nlm.nih.gov/31084327/).
- Li X, Gu F, Ding J, et al. The predictors and prognosis for unexpected reocclusion after mechanical thrombectomy: a meta-analysis. *Ann Transl Med*. 2020; 8(23): 1566, doi: [10.21037/atm-20-3465](https://doi.org/10.21037/atm-20-3465), indexed in Pubmed: [33437765](https://pubmed.ncbi.nlm.nih.gov/33437765/).
- Parsons MW, Barber PA, Desmond PM, et al. Acute hyperglycemia adversely affects stroke outcome: a magnetic resonance imaging and spectroscopy study. *Ann Neurol*. 2002; 52(1): 20–28, doi: [10.1002/ana.10241](https://doi.org/10.1002/ana.10241), indexed in Pubmed: [12112043](https://pubmed.ncbi.nlm.nih.gov/12112043/).
- Lansberg MG, Albers GW, Wijman CAC. Symptomatic intracerebral hemorrhage following thrombolytic therapy for acute ischemic stroke: a review of the risk factors. *Cerebrovasc Dis*. 2007; 24(1): 1–10, doi: [10.1159/000103110](https://doi.org/10.1159/000103110), indexed in Pubmed: [17519538](https://pubmed.ncbi.nlm.nih.gov/17519538/).
- Lee SJ, Hong JIM, Lee SE, et al. Association of fibrinogen level with early neurological deterioration among acute ischemic stroke patients with diabetes. *BMC Neurol*. 2017; 17(1): 101, doi: [10.1186/s12883017-0865-7](https://doi.org/10.1186/s12883017-0865-7), indexed in Pubmed: [28525972](https://pubmed.ncbi.nlm.nih.gov/28525972/).
- Els T, Klich J, Orszagh M, et al. Hyperglycemia in patients with focal cerebral ischemia after intravenous thrombolysis: influence on clinical outcome and infarct size. *Cerebrovasc Dis*. 2002; 13(2): 89–94, doi: [10.1159/000047756](https://doi.org/10.1159/000047756), indexed in Pubmed: [11867881](https://pubmed.ncbi.nlm.nih.gov/11867881/).
- Chung CC, Pimentel Maldonado DA, Jor'dan AJ, et al. Lower cerebral vasoreactivity as a predictor of gait speed decline in type 2 diabetes mellitus. *J Neurol*. 2018; 265(10): 2267–2276, doi: [10.1007/s00415-018-8981-x](https://doi.org/10.1007/s00415-018-8981-x), indexed in Pubmed: [30062523](https://pubmed.ncbi.nlm.nih.gov/30062523/).
- Peschillo S, Diana F, Berge J, et al. comparison of acute vascular damage caused by ADAPT versus a stent retriever device after thrombectomy in acute ischemic stroke: a histological and ultrastructural study in an animal model. *J Neurointerv Surg*. 2017 Aug. ; 9(8): 743–749.
- He G, Deng J, Zhang Y, et al. Mechanical thrombectomy injury to the arterial wall: a comparison between catheter aspiration and stent retriever. *Eur J Radiol*. 2021 Jun. ; 139: 109723.
- Lasek-Bal A, Kazibutowska Z, Gołba A, et al. Cerebral vasoreactivity in hypocapnia and hypercapnia in patients with diabetes mellitus type 2 with or without arterial hypertension. *Neurol Neurochir Pol*. 2012; 46(6): 529–535, doi: [10.5114/ninp.2012.32175](https://doi.org/10.5114/ninp.2012.32175), indexed in Pubmed: [23319220](https://pubmed.ncbi.nlm.nih.gov/23319220/).
- Desilles, J.P.; Meseguer, E.; Labreuche, J.; Lapergue, B.; Sirimarco, G. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. *Stroke*. 2013; 44: 1915–1923.
- Lu GD, Ren ZQ, Zhang JX, et al. Effects of Diabetes mellitus and admission glucose in patients receiving mechanical thrombectomy: a systematic review and meta-analysis. *Neurocrit Care*. 2018; 29(3): 426–434, doi: [10.1007/s12028-018-0562-4](https://doi.org/10.1007/s12028-018-0562-4), indexed in Pubmed: [29946761](https://pubmed.ncbi.nlm.nih.gov/29946761/).
- Kalmar PJ, Tarkanyi G, Karadi ZN, et al. the impact of diabetes mellitus and admission hyperglycemia on clinical outcomes after recanalization therapies for acute ischemic stroke: STAY ALIVE National Prospective Registry. *Life (Basel)*. 2022; 12(5), doi: [10.3390/life12050632](https://doi.org/10.3390/life12050632), indexed in Pubmed: [35629300](https://pubmed.ncbi.nlm.nih.gov/35629300/).
- de CoM, Kleinholz M, Wagner KR, et al. Normoglycemia (not hypoglycemia) optimizes outcome from middle cerebral artery occlusion. *J Cereb Blood Flow Metab*. 1994 Mar. ; 14(2): 227–36.
- Wnuk M, Popiela T, Drabik L, et al. Fasting hyperglycemia and long-term outcome in patients with acute ischemic stroke treated with mechanical thrombectomy. *J Stroke Cerebrovasc Dis*. 2020; 29(5): 104774, doi: [10.1016/j.jstrokecerebrovasdis.2020.104774](https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.104774), indexed in Pubmed: [32201103](https://pubmed.ncbi.nlm.nih.gov/32201103/).
- Merlino G, Pez S, Gigli GL, et al. Stress hyperglycemia in patients with acute ischemic stroke due to large vessel occlusion undergoing mechanical thrombectomy. *Front Neurol*. 2021; 12: 725002, doi: [10.3389/fneur.2021.725002](https://doi.org/10.3389/fneur.2021.725002), indexed in Pubmed: [34659090](https://pubmed.ncbi.nlm.nih.gov/34659090/).
- Chen X, Liu Z, Miao J, et al. High stress hyperglycemia ratio predicts poor outcome after mechanical thrombectomy for ischemic stroke. *J Stroke Cerebrovasc Dis*. 2019; 28(6): 1668–1673, doi: [10.1016/j.jstrokecerebrovasdis.2019.02.022](https://doi.org/10.1016/j.jstrokecerebrovasdis.2019.02.022), indexed in Pubmed: [30890395](https://pubmed.ncbi.nlm.nih.gov/30890395/).
- Wang L, Zhou Z, Tian X, et al. ACTUAL investigators. Impact of relative blood glucose changes on mortality risk of patient with acute ischemic stroke and treated with mechanical thrombectomy. *J Stroke Cerebrovasc Dis*. 2019; 28(1): 213–219, doi: [10.1016/j.jstrokecerebrovasdis.2018.09.036](https://doi.org/10.1016/j.jstrokecerebrovasdis.2018.09.036), indexed in Pubmed: [30539756](https://pubmed.ncbi.nlm.nih.gov/30539756/).
- Liakos Cl, Grassos CA, Babalis DK, et al. European Society of Hypertension, European Society of Cardiology. 2013 ESH/ESC guidelines for the management of arterial hypertension: what has changed in daily clinical practice? *High Blood Press Cardiovasc Prev*. 2015; 22(1): 43–53, doi: [10.1007/s40292-014-0071-2](https://doi.org/10.1007/s40292-014-0071-2), indexed in Pubmed: [25252743](https://pubmed.ncbi.nlm.nih.gov/25252743/).

24. Akbik F, Alawieh A, Dimisko L, et al. Stroke thrombectomy and aneurysm registry (star) collaborators, stroke thrombectomy and aneurysm registry (STAR). Differential effect of mechanical thrombectomy and intravenous thrombolysis in atrial fibrillation associated stroke. *J Neurointerv Surg.* 2021; 13(10): 883–888, doi: [10.1136/neurintsurg-2020-016720](https://doi.org/10.1136/neurintsurg-2020-016720), indexed in Pubmed: [33318066](https://pubmed.ncbi.nlm.nih.gov/33318066/).
25. Borggrefe J, Glück B, Maus V, et al. Clinical outcome after mechanical thrombectomy in patients with diabetes with major ischemic stroke of the anterior circulation. *World Neurosurg.* 2018; 120: e212–e220, doi: [10.1016/j.wneu.2018.08.032](https://doi.org/10.1016/j.wneu.2018.08.032), indexed in Pubmed: [30121406](https://pubmed.ncbi.nlm.nih.gov/30121406/).
26. Luchowski P, Wojczal J, Prus K, et al. Direct admission vs. secondary transfer for mechanical thrombectomy: long-term clinical outcomes from a single Polish Comprehensive Stroke Centre. *Neurol Neurochir Pol.* 2021; 55(5): 494–498, doi: [10.5603/PJNNS.a2021.0050](https://doi.org/10.5603/PJNNS.a2021.0050), indexed in Pubmed: [34346053](https://pubmed.ncbi.nlm.nih.gov/34346053/).
27. Karliński M. To drip or to mothership - the ongoing race for stroke thrombectomy. *Neurol Neurochir Pol.* 2021; 55(5): 416–417, doi: [10.5603/PJNNS.a2021.0070](https://doi.org/10.5603/PJNNS.a2021.0070), indexed in Pubmed: [34637135](https://pubmed.ncbi.nlm.nih.gov/34637135/).
28. Lin MP. Time matters greatly in acute stroke care. *Neurol Neurochir Pol.* 2020; 54(2): 104–105, doi: [10.5603/PJNNS.2020.0037](https://doi.org/10.5603/PJNNS.2020.0037), indexed in Pubmed: [32352152](https://pubmed.ncbi.nlm.nih.gov/32352152/).
29. Ye G, Gao Q, Qi P, et al. The role of diabetes mellitus on the thrombus composition in patients with acute ischemic stroke. *Interv Neuroradiol.* 2020; 26(3): 329–336, doi: [10.1177/1591019919896940](https://doi.org/10.1177/1591019919896940), indexed in Pubmed: [31924102](https://pubmed.ncbi.nlm.nih.gov/31924102/).
30. Alme KN, Knapkog AB, Næss H, et al. Is long-bout sedentary behaviour associated with long-term glucose levels 3 months after acute ischaemic stroke? A prospective observational cohort study. *BMJ Open.* 2020; 10(11): e037475, doi: [10.1136/bmjopen-2020-037475](https://doi.org/10.1136/bmjopen-2020-037475), indexed in Pubmed: [33243789](https://pubmed.ncbi.nlm.nih.gov/33243789/).
31. Osei E, den Hertog HM, Berkhemer OA, et al. MR CLEAN Investigators. Admission Glucose and Effect of Intra-Arterial Treatment in Patients With Acute Ischemic Stroke. *Stroke.* 2017; 48(5): 1299–1305, doi: [10.1161/STROKEAHA.116.016071](https://doi.org/10.1161/STROKEAHA.116.016071), indexed in Pubmed: [28389610](https://pubmed.ncbi.nlm.nih.gov/28389610/).
32. O'Connor KP, Hathidara MY, Danala G, et al. Predicting Clinical Outcome After Mechanical Thrombectomy: The GADIS (Gender, Age, Diabetes Mellitus History, Infarct Volume, and Current Smoker [corrected]) Score. *World Neurosurg.* 2020; 134: e1130–e1142, doi: [10.1016/j.wneu.2019.11.127](https://doi.org/10.1016/j.wneu.2019.11.127), indexed in Pubmed: [31786382](https://pubmed.ncbi.nlm.nih.gov/31786382/).
33. Pawelczyk M, Kaczorowska B, Baj Z. Fibrinogen concentrations in ischaemic stroke patients with metabolic disorders. *Neurol Neurochir Pol.* 2020; 54(3): 259–264, doi: [10.5603/PJNNS.a2020.0035](https://doi.org/10.5603/PJNNS.a2020.0035), indexed in Pubmed: [32293697](https://pubmed.ncbi.nlm.nih.gov/32293697/).
34. Peycheva M, Deneva T, Zahariev Z. The role of fibrinogen in acute ischaemic stroke. *Neurol Neurochir Pol.* 2021; 55(1): 74–80, doi: [10.5603/PJNNS.a2020.0094](https://doi.org/10.5603/PJNNS.a2020.0094), indexed in Pubmed: [33300114](https://pubmed.ncbi.nlm.nih.gov/33300114/).
35. Lee JS, Hwang YH, Sohn SI. Factors Contributing to an efficacious endovascular treatment for acute ischemic stroke in asian population. *Neurointervention.* 2021 Jul. ; 16(2): 91–110.
36. Kruyt ND, Biessels GJ, Devries JH, et al. Hyperglycemia in acute ischemic stroke: pathophysiology and clinical management. *Nat Rev Neurol.* 2010; 6(3): 145–155, doi: [10.1038/nrneuro.2009.231](https://doi.org/10.1038/nrneuro.2009.231), indexed in Pubmed: [20157308](https://pubmed.ncbi.nlm.nih.gov/20157308/).
37. Nowak K, Derbisz J, Jagieła J, et al. Time from stroke onset to groin puncture affects rate of recanalisation after mechanical thrombectomy: a real-life single centre experience. *Neurol Neurochir Pol.* 2020; 54(2): 156–160, doi: [10.5603/PJNNS.a2020.0024](https://doi.org/10.5603/PJNNS.a2020.0024), indexed in Pubmed: [32242914](https://pubmed.ncbi.nlm.nih.gov/32242914/).
38. Zang L, Zhang D, Yao Y, et al. Symptomatic intracranial hemorrhage in patients with admission hyperglycemia and diabetes after mechanical thrombectomy: A systematic review and meta-analysis. *Am J Emerg Med.* 2021; 45: 23–28, doi: [10.1016/j.ajem.2021.02.032](https://doi.org/10.1016/j.ajem.2021.02.032), indexed in Pubmed: [33647758](https://pubmed.ncbi.nlm.nih.gov/33647758/).
39. Nowak K, Włodarczyk E, Porębska K, et al. Mechanical thrombectomy for acute ischaemic stroke during therapeutic anticoagulation: long-term outcomes. *Neurol Neurochir Pol.* 2020; 54(6): 538–543, doi: [10.5603/PJNNS.a2020.0088](https://doi.org/10.5603/PJNNS.a2020.0088), indexed in Pubmed: [33202029](https://pubmed.ncbi.nlm.nih.gov/33202029/).
40. Kim JT, Liebeskind DS, Jahan R, et al. Impact of hyperglycemia according to the collateral status on outcomes in mechanical thrombectomy. *Stroke.* 2018 Nov. ; 49(11): 2706–2714.
41. Osei E, den Hertog HM, Berkhemer OA, et al. MR CLEAN pretrial investigators. Increased admission and fasting glucose are associated with unfavorable short-term outcome after intra-arterial treatment of ischemic stroke in the MR CLEAN pretrial cohort. *J Neurol Sci.* 2016; 371: 1–5, doi: [10.1016/j.jns.2016.10.003](https://doi.org/10.1016/j.jns.2016.10.003), indexed in Pubmed: [27871427](https://pubmed.ncbi.nlm.nih.gov/27871427/).
42. Lee SJ, Hwang YH, Hong JiM, et al. Impact of varying levels of hyperglycemia on clinicoradiographic outcomes after endovascular reperfusion treatment. *Sci Rep.* 2018; 8(1): 9832, doi: [10.1038/s41598018-28175-6](https://doi.org/10.1038/s41598018-28175-6), indexed in Pubmed: [29959399](https://pubmed.ncbi.nlm.nih.gov/29959399/).
43. Marik PE, Bellomo R, Marik PE, et al. Stress hyperglycemia: an essential survival response! *Crit Care.* 2013; 17(2): 305–e94, doi: [10.1186/cc12514](https://doi.org/10.1186/cc12514), indexed in Pubmed: [23470218](https://pubmed.ncbi.nlm.nih.gov/23470218/).
44. Levine SR, Welch KM, Helpert JA, et al. Prolonged deterioration of ischemic brain energy metabolism and acidosis associated with hyperglycemia: human cerebral infarction studied by serial 31P NMR spectroscopy. *Ann Neurol.* 1988; 23(4): 416–418, doi: [10.1002/ana.410230423](https://doi.org/10.1002/ana.410230423), indexed in Pubmed: [3382181](https://pubmed.ncbi.nlm.nih.gov/3382181/).
45. Steinberg HO, Tarshoby M, Monestel R, et al. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. *J Clin Invest.* 1997; 100(5): 1230–1239, doi: [10.1172/JCI119636](https://doi.org/10.1172/JCI119636), indexed in Pubmed: [9276741](https://pubmed.ncbi.nlm.nih.gov/9276741/).
46. Luitse MJA, Biessels GJ, Rutten GE, et al. Diabetes, hyperglycaemia, and acute ischaemic stroke. *Lancet Neurol.* 2012; 11(3): 261–271, doi: [10.1016/S1474-4422\(12\)70005-4](https://doi.org/10.1016/S1474-4422(12)70005-4), indexed in Pubmed: [22341034](https://pubmed.ncbi.nlm.nih.gov/22341034/).
47. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2019; 50(12): e344–e418.
48. Bellolio MF, Gilmore RM, Ganti L. Insulin for glycaemic control in acute ischaemic stroke. *Cochrane Database Syst Rev.* 2014(1): CD005346, doi: [10.1002/14651858.CD005346.pub4](https://doi.org/10.1002/14651858.CD005346.pub4), indexed in Pubmed: [24453023](https://pubmed.ncbi.nlm.nih.gov/24453023/).
49. Wisniewska M, Fryze W, Wiśniewska A, et al. Sex-related differences among ischaemic stroke patients treated with intravenous thrombolysis in Poland. *Neurol Neurochir Pol.* 2020; 54(3): 272–276, doi: [10.5603/PJNNS.a2020.0040](https://doi.org/10.5603/PJNNS.a2020.0040), indexed in Pubmed: [32469076](https://pubmed.ncbi.nlm.nih.gov/32469076/).
50. Wańkowicz P, Gołąb-Janowska M, Nowacki P. Risk factors for death by acute ischaemic stroke in patients from West-Pomerania, Poland. *Neurol Neurochir Pol.* 2020; 54(2): 150–155, doi: [10.5603/PJNNS.a2020.0018](https://doi.org/10.5603/PJNNS.a2020.0018), indexed in Pubmed: [32101324](https://pubmed.ncbi.nlm.nih.gov/32101324/).